Skip to content
Open access

Clinical Outcomes Following GLP-1 Receptor Agonist Initiation With Versus Without Background SGLT2 Inhibitor Therapy in Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes: A Propensity-Matched Real-World Analysis

Nov 2026 · Archives of Medical Science · 0 citations · 5 references

Abstract

SGLT2 inhibitors (SGLT2i) improve heart failure outcomes, and GLP-1 receptor agonists (GLP-1 RA) confer cardiometabolic benefit. However, outcomes after GLP-1 RA initiation according to background SGLT2i use remain uncertain. Using TriNetX, we compared GLP-1 RA initiation in patients with HFpEF and type 2 diabetes with versus without background SGLT2i. Cohorts were propensity-matched 1:1 and followed for one year, with 60-day landmark analyses. Among 27,988 matched pairs, background SGLT2i was associated with lower one-year all-cause mortality (HR 0.66, 95% CI 0.61–0.71) and major adverse cardiovascular events (MACE; HR 0.78, 95% CI 0.73–0.84; both P < 0.001). Landmark analyses were consistent for ACM (HR 0.68, 95% CI 0.63–0.75) and MACE (HR 0.83, 95% CI 0.77–0.91). In HFpEF with type 2 diabetes, GLP-1 RA initiation on a background of SGLT2i therapy was associated with lower mortality and MACE than initiation without SGLT2i.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.